Healthcare entity
Every one of those 3 sits in a single category, medical-devices. The 21-day window averages about 1 story each week. The busiest single day carried 2. Source depth averages 4.3 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, medical-devices. The 21-day window averages about 1 story each week. The busiest single day carried 2. Source depth averages 4.3 original sources per story, versus 3.4 across the same-window beat baseline. Of the tracked stories, 1 of 3 also mention Allison Transmission, the most common co-covered peer. Their average consequence score of 5.3 runs below the beat's 5.9 for that window. This profile follows 3 Healthcare stories mentioning Alcon across the period from February 25, 2026 to March 17, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 429 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alcon. Shared-story counts are live from our verified record — not editorial picks.
Deal Termination
Alcon and LENSAR announce the end of the merger agreement due to FTC opposition.
2026 Strategic Focus
Strategic focus shifts toward AI-integrated ophthalmic surgical suites for the 2026 fiscal year.
Q4 2025 Earnings Report
Alcon reports Q4 2025 earnings, beating analyst expectations in key segments.
FTC Investigation
The FTC intensifies its review of the merger, focusing on the ophthalmic laser market.
Digital Health Expansion
Company announces expansion of its digital health platform for surgical planning.
Global ATIOL Rollout
Alcon begins global rollout of its latest advanced technology intraocular lens (ATIOL).
Merger Agreement
Alcon and LENSAR enter into a definitive agreement for Alcon to acquire LENSAR.
Alcon has officially terminated its merger agreement with LENSAR, a leader in femtosecond laser technology, citing insurmountable opposition from the Federal Trade Commission (FTC). The collapse of the deal highlights increasing regulatory scrutiny over consolidation within the specialized medical device and ophthalmic surgery sectors.
Alcon reported strong Q4 2025 results, highlighting robust demand in surgical equipment and vision care products. The company's performance signals a steady recovery in elective procedures and a growing market for advanced ophthalmic technologies, contrasting with volatility in other industrial sectors.
Alcon reported a Q4 core EPS of $0.78, narrowly missing the FactSet consensus of $0.79. While the miss was marginal, it highlights the ongoing pressure on medical device margins and the defensive posture of the healthcare sector compared to industrial peers.
Source: Marketscreener · Marketscreener
Alcon is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
